SGLT2 inhibitors in T2DM are associated with reduced gastrointestinal cancer risk
Vancouver, Canada — The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancer in patients with: type 2 diabetes New evidence emerges in comparison with dipeptidyl peptidase IV (DPP4) inhibitors. SGLT2 inhibitors were found to be better than DPP4 inhibitors in reducing the risk of colorectal, liver, […]
Cureus A systematic review on the efficacy and safety of selective serotonin reuptake inhibitors in gastrointestinal motility…Gastrointestinal motility disorders have been thought to occur due to an imbalance in gut-brain axis interactions. ..August 4, 2022
Cureus A systematic review on the efficacy and safety of selective serotonin reuptake inhibitors in gastrointestinal motility…Gastrointestinal motility disorders have been thought to occur due to an imbalance in gut-brain axis interactions. ..August 4, 2022